Ivor Royston: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{short description|American oncologist and entrepreneur}} | ||
{{Use American English|date=October 2023}} | {{Use American English|date=October 2023}} | ||
{{Use mdy dates|date=October 2023}} | {{Use mdy dates|date=October 2023}} | ||
[[File:Ivor_Royston_headshot.jpg|thumb|right|Ivor Royston]] | |||
==Early | '''Ivor Royston''' is an American [[oncologist]] and [[entrepreneur]] known for his pioneering work in the field of [[biotechnology]]. He is a co-founder of [[Hybritech]], one of the first biotechnology companies, and has been influential in the development of [[monoclonal antibodies]] for cancer treatment. | ||
Ivor Royston was born in 1945 | |||
==Early life and education== | |||
Ivor Royston was born in 1945. He pursued his undergraduate studies at [[Johns Hopkins University]], where he developed an interest in [[medicine]] and [[biological sciences]]. Royston went on to earn his [[Doctor of Medicine|M.D.]] from the [[University of Rochester]] in 1970. | |||
==Career== | ==Career== | ||
===Academic | ===Academic career=== | ||
After completing his medical degree | After completing his medical degree, Royston joined the faculty at the [[University of California, San Diego]] (UCSD), where he focused on [[cancer research]]. His work at UCSD laid the foundation for his later ventures into biotechnology. | ||
=== | ===Biotechnology ventures=== | ||
In 1978, Royston co-founded [[Hybritech]] with [[Howard Birndorf]]. Hybritech was one of the first companies to commercialize [[monoclonal antibodies]], which are now a cornerstone in the treatment of various cancers. The success of Hybritech paved the way for the growth of the biotechnology industry in [[San Diego]]. | |||
Royston has also been involved in the founding of several other biotechnology companies, including [[Idec Pharmaceuticals]], which later merged with [[Biogen]] to form [[Biogen Idec]]. | |||
Royston | |||
== | ===Current work=== | ||
Royston continues to be active in the biotechnology field, serving on the boards of various companies and organizations. He is also involved in venture capital, helping to fund and guide new biotechnology startups. | |||
== | ==Awards and recognition== | ||
Ivor Royston | Ivor Royston has received numerous awards for his contributions to medicine and biotechnology. His work has been recognized by various professional organizations, and he is considered a pioneer in the field of [[biotechnology]]. | ||
==Related | ==Related pages== | ||
* [[Monoclonal antibody | * [[Monoclonal antibody]] | ||
* [[Biotechnology]] | * [[Biotechnology]] | ||
* [[Cancer treatment]] | * [[Cancer treatment]] | ||
* [[ | * [[Hybritech]] | ||
[[Category:American oncologists]] | [[Category:American oncologists]] | ||
[[Category:American medical researchers]] | [[Category:American medical researchers]] | ||
[[Category: | [[Category:Biotechnology]] | ||
[[Category:Living people]] | |||
[[Category:1945 births]] | [[Category:1945 births]] | ||
Latest revision as of 14:19, 21 February 2025
American oncologist and entrepreneur
Ivor Royston is an American oncologist and entrepreneur known for his pioneering work in the field of biotechnology. He is a co-founder of Hybritech, one of the first biotechnology companies, and has been influential in the development of monoclonal antibodies for cancer treatment.
Early life and education[edit]
Ivor Royston was born in 1945. He pursued his undergraduate studies at Johns Hopkins University, where he developed an interest in medicine and biological sciences. Royston went on to earn his M.D. from the University of Rochester in 1970.
Career[edit]
Academic career[edit]
After completing his medical degree, Royston joined the faculty at the University of California, San Diego (UCSD), where he focused on cancer research. His work at UCSD laid the foundation for his later ventures into biotechnology.
Biotechnology ventures[edit]
In 1978, Royston co-founded Hybritech with Howard Birndorf. Hybritech was one of the first companies to commercialize monoclonal antibodies, which are now a cornerstone in the treatment of various cancers. The success of Hybritech paved the way for the growth of the biotechnology industry in San Diego.
Royston has also been involved in the founding of several other biotechnology companies, including Idec Pharmaceuticals, which later merged with Biogen to form Biogen Idec.
Current work[edit]
Royston continues to be active in the biotechnology field, serving on the boards of various companies and organizations. He is also involved in venture capital, helping to fund and guide new biotechnology startups.
Awards and recognition[edit]
Ivor Royston has received numerous awards for his contributions to medicine and biotechnology. His work has been recognized by various professional organizations, and he is considered a pioneer in the field of biotechnology.
